TAK 659

Drug Profile

TAK 659

Alternative Names: TAK-659

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Acute myeloid leukaemia
  • Phase I Breast cancer; Gastric cancer; Head and neck cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 26 Mar 2018 Millennium Pharmaceuticals withdraws a phase I trial prior to enrolment due to business decision for Solid tumours and Lymphoma (Metastatic disease, Late-stage disease, Second-line or greater) in USA (PO) (NCT03359733)
  • 26 Mar 2018 Takeda withdraws a phase I pharmacokinetics trial prior to enrolment due to business decision for Solid tumours and Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (PO) (NCT03338881)
  • 16 Feb 2018 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Germany (PO) (NCT03357627)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top